Steve Schonfeld’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12M | Sell |
147,425
-170,980
| -54% | -$12.3M | 0.04% | 361 |
|
|
2026
Q1 | $21.7M | Buy |
+318,405
| New | +$22.5M | 0.15% | 134 |
|
|
2025
Q4 | – | Sell |
-23,173
| Closed | -$1.42M | – | 2489 |
|
|
2025
Q3 | $1.42M | Sell |
23,173
-19,086
| -45% | -$994K | 0.01% | 1208 |
|
|
2025
Q2 | $2.06M | Sell |
42,259
-23,592
| -36% | -$1.12M | 0.01% | 966 |
|
|
2025
Q1 | $3.36M | Sell |
65,851
-56,429
| -46% | -$2.82M | 0.02% | 690 |
|
|
2024
Q4 | $5.52M | Sell |
122,280
-66,953
| -35% | -$2.87M | 0.03% | 473 |
|
|
2024
Q3 | $7.02M | Buy |
189,233
+161,572
| +584% | +$5.41M | 0.05% | 410 |
|
|
2024
Q2 | $846K | Buy |
+27,661
| New | +$896K | 0.01% | 1283 |
|
|
2022
Q4 | – | Sell |
-5,745
| Closed | -$289K | – | 2926 |
|
|
2022
Q3 | $289K | Sell |
5,745
-32,025
| -85% | -$1.57M | ﹤0.01% | 2111 |
|
|
2022
Q2 | $1.51M | Buy |
+37,770
| New | +$1.32M | 0.01% | 838 |
|
|
2021
Q3 | – | Sell |
-60,100
| Closed | -$2.54M | – | 2405 |
|
|
2021
Q2 | $2.54M | Buy |
+60,100
| New | +$2.58M | 0.03% | 645 |
|
|
2020
Q2 | – | Sell |
-8,278
| Closed | -$369K | – | 1502 |
|
|
2020
Q1 | $369K | Buy |
+8,278
| New | +$417K | 0.02% | 674 |
|
|
2019
Q3 | – | Sell |
-9,600
| Closed | -$432K | – | 1192 |
|
|
2019
Q2 | $432K | Buy |
+9,600
| New | +$379K | 0.02% | 673 |
|
|
2019
Q1 | – | Sell |
-31,400
| Closed | -$1.08M | – | 1204 |
|
|
2018
Q4 | $1.08M | Sell |
31,400
-113,300
| -78% | -$4.07M | 0.04% | 466 |
|
|
2018
Q3 | $6.8M | Sell |
144,700
-63,600
| -31% | -$2.63M | 0.3% | 88 |
|
|
2018
Q2 | $7.03M | Buy |
208,300
+188,497
| +952% | +$5.88M | 0.38% | 72 |
|
|
2018
Q1 | $536K | Buy |
+19,803
| New | +$502K | 0.04% | 459 |
|
|
2017
Q4 | – | Sell |
-68,739
| Closed | -$1.38M | – | 854 |
|
|
2017
Q3 | $1.38M | Buy |
+68,739
| New | +$1.35M | 0.13% | 210 |
|
|
2017
Q2 | – | Sell |
-46,232
| Closed | -$455K | – | 737 |
|
|
2017
Q1 | $455K | Buy |
+46,232
| New | +$560K | 0.05% | 386 |
|
|
2016
Q4 | – | Sell |
-54,605
| Closed | -$765K | – | 635 |
|
|
2016
Q3 | $765K | Buy |
+54,605
| New | +$444K | 0.13% | 216 |
|
|
2016
Q2 | – | Sell |
-11,211
| Closed | -$72K | – | 514 |
|
|
2016
Q1 | $72K | Buy |
+11,211
| New | +$195K | 0.03% | 291 |
|
Other funds holding PTCT
RI
JT
Steve Schonfeld's PTCT Position: Q2 2026 in Review
Steve Schonfeld reduced its PTC Therapeutics (PTCT) stake by 54% in Q2 2026, selling an estimated $12.3M and leaving 147,425 shares worth $12M. The position accounts for 0.04% of the portfolio, ranked #361.
Steve Schonfeld first reported a position in PTCT in Q1 2016 and has held it in 21 quarters since. The position peaked at $21.7M in Q1 2026. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Steve Schonfeld held 147,425 shares of PTC Therapeutics worth $12M as of Q2 2026.
- Steve Schonfeld sold 170,980 PTC Therapeutics shares in Q2 2026, an estimated $12.3M.
- PTC Therapeutics made up 0.04% of Steve Schonfeld's portfolio in Q2 2026, its #361 holding.
- Steve Schonfeld first reported a position in PTC Therapeutics in Q1 2016 and has held it in 21 quarters since.
- Steve Schonfeld's PTC Therapeutics position peaked at $21.7M in Q1 2026.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.